Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$2.31 +4.5%	$1.50	$1.03 ▼ $2.57	$462.78M	1.22	1.60 million shs	2.93 million shs
GLUE Monte Rosa Therapeutics	$4.06 +1.8%	$4.47	$3.21 ▼ $12.40	$249.73M	1.52	1.06 million shs	711,536 shs
LXEO Lexeo Therapeutics	$2.74 +1.5%	$3.08	$1.45 ▼ $19.50	$90.96M	1.27	497,481 shs	564,287 shs
PROK ProKidney	$0.71 -3.3%	$0.79	$0.46 ▼ $4.35	$206.59M	1.5	676,617 shs	364,089 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	+7.28%	+7.80%	+51.37%	+27.75%	+37.27%
GLUE Monte Rosa Therapeutics	+0.50%	-4.09%	-21.15%	-30.97%	-4.09%
LXEO Lexeo Therapeutics	-4.26%	-23.51%	-26.63%	-14.56%	-82.54%
PROK ProKidney	+2.73%	-7.99%	-28.43%	-43.85%	-78.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	2.267 of 5 stars	3.7	1.0	2.5	2.5	0.6
GLUE Monte Rosa Therapeutics	1.8839 of 5 stars	3.4	0.0	2.2	3.3	0.6
LXEO Lexeo Therapeutics	2.8536 of 5 stars	3.6	2.0	2.6	2.5	1.3
PROK ProKidney	2.1499 of 5 stars	3.3	0.0	2.7	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.33	Buy	$8.67	275.18% Upside
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$15.50	281.77% Upside
LXEO Lexeo Therapeutics	3.17	Buy	$20.20	637.23% Upside
PROK ProKidney	2.50	Moderate Buy	$5.00	608.42% Upside

Current Analyst Ratings Breakdown

Latest LXEO, GLUE, PROK, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	ATAI Atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	ATAI Atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/26/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/25/2025	LXEO Lexeo Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00
3/25/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/24/2025	LXEO Lexeo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $18.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$1.86M	248.41	N/A	N/A	$1.47 per share	1.57
GLUE Monte Rosa Therapeutics	$159.49M	1.57	N/A	N/A	$3.58 per share	1.13
LXEO Lexeo Therapeutics	$650K	139.94	N/A	N/A	$4.26 per share	0.64
PROK ProKidney	$306K	675.12	N/A	N/A	($4.84) per share	-0.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.91	N/A	N/A	N/A	N/A	-65.75%	-52.71%	8/12/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$135.35M	$0.08	N/A	N/A	N/A	N/A	-62.68%	-38.83%	8/14/2025 (Estimated)
LXEO Lexeo Therapeutics	-$66.39M	-$3.30	N/A	N/A	N/A	N/A	-57.66%	-48.18%	8/11/2025 (Estimated)
PROK ProKidney	-$35.47M	-$0.60	N/A	N/A	N/A	N/A	N/A	-10.24%	8/8/2025 (Estimated)

Latest LXEO, GLUE, PROK, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A
3/20/2025	Q4 2024	GLUE Monte Rosa Therapeutics	-$0.37	$0.23	+$0.60	$0.23	$43.73 million	$14.00 million
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
3/17/2025	Q4 2024	PROK ProKidney	-$0.14	-$0.17	-$0.03	-$0.17	N/A	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
GLUE Monte Rosa Therapeutics	N/A	6.03	6.03
LXEO Lexeo Therapeutics	0.01	5.95	5.95
PROK ProKidney	N/A	17.08	17.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
GLUE Monte Rosa Therapeutics	79.96%
LXEO Lexeo Therapeutics	60.67%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	31.20%
GLUE Monte Rosa Therapeutics	6.90%
LXEO Lexeo Therapeutics	4.50%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	200.34 million	115.45 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.44 million	Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.58 million	Not Optionable
PROK ProKidney	3	292.70 million	170.65 million	Optionable

LXEO, GLUE, PROK, and ATAI Headlines

Recent News About These Companies

ProKidney quarterly loss grows as it nears two key milestones

May 15, 2025 | journalnow.com

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

May 12, 2025 | globenewswire.com

Another Big Office Landlord Tests Sales Climate

May 12, 2025 | bankerandtradesman.com

PROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and More

May 9, 2025 | nasdaq.com

ProKidney (PROK) Expected to Announce Quarterly Earnings on Friday

May 4, 2025 | marketbeat.com

Why ProKidney Corp.’s (PROK) Stock Is Down 6.09%

April 28, 2025 | aaii.com

Insider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of Stock

April 25, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 7.90%

April 17, 2025 | aaii.com

ProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in Stock

April 17, 2025 | insidertrades.com

Greensboro’s Once Great Win Is Now A ProKidney Failure

April 16, 2025 | rhinotimes.com

Control Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

April 15, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 9.90%

April 10, 2025 | aaii.com

Why ProKidney Corp.’s (PROK) Stock Is Down 14.87%

April 8, 2025 | aaii.com

ProKidney Corp.

March 30, 2025 | wsj.com

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation

March 27, 2025 | finance.yahoo.com

Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)

March 21, 2025 | zacks.com

ProKidney reports larger loss in 2024 as production resumes

March 18, 2025 | journalnow.com

ProKidney reports FY24 EPS (62c), consensus (59c)

March 17, 2025 | markets.businessinsider.com

ProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney Disease

March 17, 2025 | quiverquant.com

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

March 17, 2025 | globenewswire.com

Why ProKidney Corp.’s (PROK) Stock Is Down 10.96%

February 26, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, GLUE, PROK, and ATAI Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$2.31 +0.10 (+4.52%)

Closing price 04:00 PM Eastern

Extended Trading

$2.30 -0.02 (-0.65%)

As of 06:55 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.06 +0.07 (+1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$4.06 0.00 (0.00%)

As of 04:04 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$2.74 +0.04 (+1.48%)

Closing price 04:00 PM Eastern

Extended Trading

$2.77 +0.03 (+1.09%)

As of 06:59 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

ProKidney NASDAQ:PROK

$0.71 -0.02 (-3.32%)

Closing price 04:00 PM Eastern

Extended Trading

$0.74 +0.04 (+5.55%)

As of 05:22 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time